Concepedia

Joseph M. Flynn

JM

80

Publications

8.6K

Citations

39

H-Index

1990

Active since

Affiliations

The Ohio State University(Current)

University of Bath

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute

The Ohio State University Wexner Medical Center

Pharmacyclics (United States)

Joseph M. Flynn is an author at The Ohio State University specializing in medicine, oncology, and immunology.

ORCID

Top concepts

Publications per year

1990–2021

80

Publications

80

Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765

Sarah E. M. Herman, Amber Gordon, Erin Hertlein et al. · Blood · 2011 · 789 citations · Full text

Invited review article: Strategies and processes for high quality wire arc additive manufacturing

Chloe Cunningham, Joseph M. Flynn, Alborz Shokrani et al. · Additive manufacturing · 2018 · 785 citations

, , +7

Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes

Jason A. Dubovsky, Kyle A. Beckwith, Gayathri Natarajan et al. · Blood · 2013 · 783 citations · Full text

Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia

Kami J. Maddocks, Amy S. Ruppert, Gerard Lozanski et al. · JAMA Oncology · 2015 · 568 citations · Full text

Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals

Sarah E.M. Herman, Amber Gordon, Amy J. Wagner et al. · Blood · 2010 · 541 citations · Full text

Rows per page

1–5 of 80